6,496 Shares in Guardant Health, Inc. $GH Purchased by Alta Wealth Advisors LLC

Alta Wealth Advisors LLC bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the third quarter, Holdings Channel.com reports. The fund bought 6,496 shares of the company’s stock, valued at approximately $406,000.

A number of other hedge funds have also recently bought and sold shares of the stock. IFP Advisors Inc grew its holdings in shares of Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after purchasing an additional 334 shares in the last quarter. Signaturefd LLC lifted its position in Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares during the period. Allworth Financial LP lifted its position in Guardant Health by 358.4% in the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares during the period. Sound Income Strategies LLC acquired a new stake in Guardant Health during the third quarter worth $38,000. Finally, FNY Investment Advisers LLC bought a new stake in Guardant Health in the 2nd quarter valued at $62,000. 92.60% of the stock is owned by institutional investors.

Guardant Health Trading Down 0.0%

NASDAQ GH opened at $114.74 on Tuesday. Guardant Health, Inc. has a 12 month low of $34.88 and a 12 month high of $120.74. The stock has a 50-day simple moving average of $105.61 and a 200 day simple moving average of $78.27. The company has a market capitalization of $14.46 billion, a PE ratio of -35.74 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same quarter last year, the business earned ($0.88) earnings per share. The firm’s revenue for the quarter was up 38.5% on a year-over-year basis. As a group, sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on GH shares. Stifel Nicolaus lifted their price objective on Guardant Health from $100.00 to $120.00 and gave the company a “buy” rating in a report on Friday, January 9th. Mizuho set a $135.00 target price on Guardant Health in a research report on Friday, January 9th. Morgan Stanley boosted their price target on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Canaccord Genuity Group upped their price target on Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Finally, Guggenheim increased their price objective on Guardant Health from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Monday. Twenty-one analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $103.76.

Insider Buying and Selling at Guardant Health

In other news, insider Terilyn J. Monroe sold 8,571 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total transaction of $977,865.39. Following the completion of the transaction, the insider directly owned 20,990 shares in the company, valued at $2,394,749.10. This represents a 28.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Medina Manuel Hidalgo sold 1,250 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $105.00, for a total value of $131,250.00. Following the completion of the transaction, the director owned 797 shares of the company’s stock, valued at approximately $83,685. This represents a 61.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 445,123 shares of company stock valued at $46,600,702 over the last quarter. 6.10% of the stock is currently owned by corporate insiders.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.